600976 Jianmin Pharmaceutical Group
- 64.30
- +3.78+6.25%
Jianmin Pharmaceutical Group News
Jianmin Group (600976): Continued to provide performance growth based on the pediatric brand single product Tibeiuhuang
Key investment points: Deeply cultivate pediatric OTC brand large single product Longmu Zhuang bone pellets. 1) In 2022, OTC pediatric proprietary Chinese medicines had the highest market share and strong market competitiveness. 2) Longmu Bone Granules are suitable for a wide range of people and mainly promote a broad market for children. 3
Jianmin Pharmaceutical Group Co.,Ltd.'s (SHSE:600976) Shares Lagging The Market But So Is The Business
With a price-to-earnings (or "P/E") ratio of 17.5x Jianmin Pharmaceutical Group Co.,Ltd. (SHSE:600976) may be sending bullish signals at the moment, given that almost half of all companies in China ha
Jianmin Group (600976): Performance is in line with expectations, sports training, Niu Huang's performance is outstanding
Key investment events: Jianmin Group released its 2024 quarterly report. During the reporting period, it achieved revenue of 970 million yuan (-4.27% year over year), net profit to mother of 100 million yuan (-0.04% year over year), net profit of zero non-return to mother
Jianmin Group (600976.SH) announced first-quarter results, net profit of 99.52 million yuan, a year-on-year decrease of 0.04%
Jianmin Group (600976.SH) disclosed its report for the first quarter of 2024. The company achieved 9.7 revenue during the reporting period...
Jianmin Group (600976.SH) will distribute 1.2 yuan per share in 2023. The stock registration date is April 25
Jianmin Group (600976.SH) issued an announcement that the company will implement the 2023 annual equity distribution, distributed per share...
Jianmin Group (600976.SH): The phase II clinical trial of the company's product Tongzheng Granule is in the summary stage
Gelonghui April 16 丨 Some investors asked Jianmin Group (600976.SH) through an interactive platform: How is your company's clinical progress in Tongzheng Granule? How long until launch? Jianmin Group (600976.SH) replied: The second phase clinical trial of the company's product Tongzheng Granule is in the summary stage. There is some uncertainty in the development of new drugs. Investors are kindly requested to pay attention to investment risks.
Jianmin Pharma Gets Nod to Market Asthma Drug
Jianmin Pharmaceutical Group (SHA:600976) obtained approval from China's National Medical Products Administration to market its terbutaline sulfate atomized inhalation product, the company said in a T
Express News | Jianmin Group: Terbutaline sulfate nebulized inhalation solution approved for listing
Declining Stock and Solid Fundamentals: Is The Market Wrong About Jianmin Pharmaceutical Group Co.,Ltd. (SHSE:600976)?
Jianmin Pharmaceutical GroupLtd (SHSE:600976) has had a rough three months with its share price down 9.9%. But if you pay close attention, you might gather that its strong financials could mean that
Jianmin Pharmaceutical GroupLtd's (SHSE:600976) Solid Profits Have Weak Fundamentals
Investors were disappointed with Jianmin Pharmaceutical Group Co.,Ltd.'s (SHSE:600976) earnings, despite the strong profit numbers. We think that the market might be paying attention to some underlyi
Jianmin Group (600976) Annual Report Review Report: Performance growth is in line with expectations, the growth rate of Longmuzhuang bone pellets is impressive
Jianmin Group released its 2023 annual report: Performance growth is in line with expectations. In 2023, it achieved operating income of 4.213 billion yuan, an increase of 15.72% over the previous year; achieved net profit of 521 million yuan to mother, an increase of 27 million yuan over the previous year.
Jianmin Group (600976) 2023 Annual Report Review: Performance Growth Meets Expectations
Incident: Jianmin Group released its 2023 annual report, achieving revenue of 4.213 billion yuan (YoY +15.72%); net profit attributable to mother of 521 million yuan (YoY +27.78%); net profit after deducting non-return to mother of 438 million yuan
Jianmin Group (600976): The gross margin of the main business increased steadily, and Jianmin Dapeng's profit continued to grow
Incident Jianmin Group released its 2023 annual report. The company's revenue for 23 years was 4.213 billion yuan, up 15.72% year on year; net profit to mother was 521 million yuan, up 27.78% year on year; net income without return to mother
Jianmin Group (600976): Second-tier product, cultivating beef yolk in vitro with high elastomer, is growing steadily
Event: On March 15, 2024, Jianmin Group issued an announcement: in 2023, the company achieved operating income of 4.213 billion yuan (YoY +15.72%) and net profit to mother of 521 million yuan (year-on-year +27.78 million yuan)
Jianmin Group (600976): The performance is in line with expectations and the profit level is stable
Key investment events: Jianmin Group released its 2023 annual report. During the reporting period, it achieved revenue of 4.213 billion yuan (YoY +15.72%), net profit to mother of 521 million yuan (YoY +27.78%, after adjustment), net profit of 521 million yuan (YoY +27.78%, adjusted), net profit
Jianmin Group (600976): OTC increases brand creation and gradual introduction of new prescription products
Incident: The company announced its 2023 annual report, achieving operating income of 4.213 billion yuan (+15.72%), net profit to mother of 521 million yuan (+27.78%), and net profit of non-return to mother of 438 million yuan (+17)
Retail Investors Among Jianmin Pharmaceutical Group Co.,Ltd.'s (SHSE:600976) Largest Shareholders, Saw Gain in Holdings Value After Stock Jumped 8.4% Last Week
Key Insights Significant control over Jianmin Pharmaceutical GroupLtd by retail investors implies that the general public has more power to influence management and governance-related decisions 51%
Express News | Jianmin Group: Net profit attributable to mother in 2023 was 521 million yuan, up 27.78% year-on-year
Jianmin Group (600976.SH): In 2024, the company will continue to build the “Dragon Ball” brand
Gelonghui, March 5 | Jianmin Group (600976.SH) recently said during a survey receiving institutional investors that Longmu is the company's exclusive product, a Class B drug under the National Health Insurance. The 2023 National Health Insurance Catalogue lifted restrictions on the scope of reimbursement for “pediatric rickets,” which will have a positive effect on the promotion of Longmu on the hospital line. In 2024, the company will continue to build the “Longmu” brand, increase accurate advertising and professional brand building; increase refined marketing management, further decline in sales, increase team building and evidence-based medical research, and strive to promote a continuous increase in Longmu's sales revenue
Jianmin Group (600976.SH): Spleen Health and Blood Granules will be the third single product the OTC channel is focusing on
Gelonghui, March 5, 丨 Jianmin Group (600976.SH) recently said during a survey of institutional investors that Jianmin Group () will be the third single product focused on the OTC channel. The product has the effects of strengthening the spleen and stomach, nourishing blood and calming, and is used for children with poor spleen and spleen iron deficiency anemia, and adult qi and blood deficiency iron deficiency anemia; it is a national-based drug type. As the company's exclusive product, we have sorted out the channel and sales model to optimize the value chain. An OTC channel single product created, I hope to have one Good development.
Analysis
Price Target
No Data
